Association Between Clinical Effect of Continuous Morphine Administration After Surgery and Pharmacogenetics

Fondazione IRCCS Policlinico San Matteo di Pavia

Overview

Identification of the genetic polymorphisms that could be correlated either with a better clinical response or with a major predisposition of patients to develop tolerance and/or side effects to the treatment with morphine.

Valuation of the rescue doses necessary to maintain NRS\<4 in the first 24 hours post-surgery in the two groups of patients, A e B. Group A: homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene (about 80%); group B: both homozygous and heterozygous patients for the less frequent allele (about 20%).

Study Type

OBSERVATIONAL

Conditions

Anesthesia Surgery

Interventions

morphine chlorhydrateDRUG

The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation. At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h. Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS\<4 maximum x 3 daily. Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h).

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion criteria: * Males and females over 18 years, under 75 years, scheduled for postoperative pain control with continuous morphine administration * HIV negative * Classification American Society of Anesthesiologists (ASA) I: without systemic disease * Classification ASA II or III (mild systemic disease or severe systemic disease that limits the activity without invalidity). * Undergoing abdominal and urologic major surgery (neither urgent nor emergency surgery) * Signed informed consent Exclusion criteria: * Usual assumption of analgesic opioids * Cognitive alterations nor mental retardation * Severe hepatic/renal insufficiency (cholinesterase \<3000 mU/ml, total bilirubinaemia \<2 mg/dl and creatininaemia \<1.2 mg/dl) * Inpatients in intensive therapy, either with sedation and/or mechanic ventilation. * Allergies to morphine and derivates

Locations (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Outcomes

Primary Outcomes

Assessment of the rescue doses in the two groups homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene; group B: both homozygous and heterozygous patients for the less frequent allele

Time frame: first 24 h after surgery

Secondary Outcomes

Variants at the loci OPRM1, COMT, UGTs, ESR1,towards median pain measure

Frequency of the variants at the loci OPRM1, COMT, UGTs, ESR1, both in patients with NRS ≤4 and in those having NRS \>4 at least once during 24 hours.

Time frame: during 24 h postsurgery

Variants at the loci OPRM1, COMT, UGTs, ESR1,towards median pain measure

Frequency of the variants at the loci OPRM1, COMT, UGTs, ESR1, both in patients with NRS ≤4 and in those having NRS \>4 at least once during the period between 24-48 hours postsurgery.

Time frame: period between 24 - 48 h postsurgery

Pharmacokinetics of morphine during continuous administration after surgery

Pharmacokinetic study of both morphine and its principal active and/or toxic metabolites (M3G and M6G).

Time frame: 48 h after surgery

Detection of the possible side effects.

Detection of the possible side effects after continuous morphine administration

Time frame: 72 h postopratively

Detection of the association between M3G/M6G ratio and polymorphisms of UGTs

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.